Baseline and follow-up association of the MAX-PC in Men with newly diagnosed prostate cancer

Andrea M. Tavlarides, Steven C. Ames, David D. Thiel, Nancy N. Diehl, Alexander Parker

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective The objective of this paper is to conduct a prospective, longitudinal study employing the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) to examine the baseline and follow-up association of prostate cancer (PCa)-specific anxiety, health-related quality of life (HRQOL), and PCa aggressiveness in men with newly-diagnosed PCa undergoing prostatectomy at our institution. Methods From our prospective PCa registry, we identified a total of 350 men with newly-diagnosed PCa who completed the MAX-PC and the Expanded Prostate Cancer Index Composite (EPIC) at baseline and one-year following surgery. Scores on both measures were compared with clinical measure and demographics using the Wilcoxon Rank Sum, Fisher's exact, and Cochran-Armitage Trend tests. Spearman test was used to assess correlation at between the MAX-PC and EPIC at baseline and one-year. Results Baseline overall MAX-PC measures were correlated with measures at one-year (r = 0.5479, p < 0.001). Those reporting high anxiety at one-year were more likely to have Gleason score > 6 (p = 0.004), T-Stage ≥ 2C disease (p = 0.004), and a postoperative prostate-specific antigen (PSA) > 0.1 (p = 0.002); however, this did not apply to all anxious patients. Baseline EPIC sexual function scores were predictive of follow-up EPIC sexual function scores as well (r = 0.5790, p < 0.001). Depression was noted as a problem in 16% of patients at follow-up. Conclusions Our data suggests that the MAX-PC could be used at baseline as a tool to determine who may benefit from psychological intervention pre-PCa and post-PCa treatment. In terms of individualized medicine, behavioral therapy may be the most beneficial in improving HRQOL for younger patients, those with advanced stage disease, and more specifically those whose anxiety outweighs their actual prognosis.

Original languageEnglish (US)
Pages (from-to)451-457
Number of pages7
JournalPsycho-Oncology
Volume24
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Prostatic Neoplasms
Anxiety
Quality of Life
Precision Medicine
Prostate-Specific Antigen
Prostatectomy
Longitudinal Studies
Registries

Keywords

  • anxiety
  • cancer
  • oncology
  • prostate cancer
  • quality of life
  • surgery

ASJC Scopus subject areas

  • Oncology
  • Psychiatry and Mental health
  • Experimental and Cognitive Psychology

Cite this

Baseline and follow-up association of the MAX-PC in Men with newly diagnosed prostate cancer. / Tavlarides, Andrea M.; Ames, Steven C.; Thiel, David D.; Diehl, Nancy N.; Parker, Alexander.

In: Psycho-Oncology, Vol. 24, No. 4, 01.04.2015, p. 451-457.

Research output: Contribution to journalArticle

Tavlarides, Andrea M. ; Ames, Steven C. ; Thiel, David D. ; Diehl, Nancy N. ; Parker, Alexander. / Baseline and follow-up association of the MAX-PC in Men with newly diagnosed prostate cancer. In: Psycho-Oncology. 2015 ; Vol. 24, No. 4. pp. 451-457.
@article{f156b22fd95e4e62a1927853c8ff4593,
title = "Baseline and follow-up association of the MAX-PC in Men with newly diagnosed prostate cancer",
abstract = "Objective The objective of this paper is to conduct a prospective, longitudinal study employing the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) to examine the baseline and follow-up association of prostate cancer (PCa)-specific anxiety, health-related quality of life (HRQOL), and PCa aggressiveness in men with newly-diagnosed PCa undergoing prostatectomy at our institution. Methods From our prospective PCa registry, we identified a total of 350 men with newly-diagnosed PCa who completed the MAX-PC and the Expanded Prostate Cancer Index Composite (EPIC) at baseline and one-year following surgery. Scores on both measures were compared with clinical measure and demographics using the Wilcoxon Rank Sum, Fisher's exact, and Cochran-Armitage Trend tests. Spearman test was used to assess correlation at between the MAX-PC and EPIC at baseline and one-year. Results Baseline overall MAX-PC measures were correlated with measures at one-year (r = 0.5479, p < 0.001). Those reporting high anxiety at one-year were more likely to have Gleason score > 6 (p = 0.004), T-Stage ≥ 2C disease (p = 0.004), and a postoperative prostate-specific antigen (PSA) > 0.1 (p = 0.002); however, this did not apply to all anxious patients. Baseline EPIC sexual function scores were predictive of follow-up EPIC sexual function scores as well (r = 0.5790, p < 0.001). Depression was noted as a problem in 16{\%} of patients at follow-up. Conclusions Our data suggests that the MAX-PC could be used at baseline as a tool to determine who may benefit from psychological intervention pre-PCa and post-PCa treatment. In terms of individualized medicine, behavioral therapy may be the most beneficial in improving HRQOL for younger patients, those with advanced stage disease, and more specifically those whose anxiety outweighs their actual prognosis.",
keywords = "anxiety, cancer, oncology, prostate cancer, quality of life, surgery",
author = "Tavlarides, {Andrea M.} and Ames, {Steven C.} and Thiel, {David D.} and Diehl, {Nancy N.} and Alexander Parker",
year = "2015",
month = "4",
day = "1",
doi = "10.1002/pon.3605",
language = "English (US)",
volume = "24",
pages = "451--457",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Baseline and follow-up association of the MAX-PC in Men with newly diagnosed prostate cancer

AU - Tavlarides, Andrea M.

AU - Ames, Steven C.

AU - Thiel, David D.

AU - Diehl, Nancy N.

AU - Parker, Alexander

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Objective The objective of this paper is to conduct a prospective, longitudinal study employing the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) to examine the baseline and follow-up association of prostate cancer (PCa)-specific anxiety, health-related quality of life (HRQOL), and PCa aggressiveness in men with newly-diagnosed PCa undergoing prostatectomy at our institution. Methods From our prospective PCa registry, we identified a total of 350 men with newly-diagnosed PCa who completed the MAX-PC and the Expanded Prostate Cancer Index Composite (EPIC) at baseline and one-year following surgery. Scores on both measures were compared with clinical measure and demographics using the Wilcoxon Rank Sum, Fisher's exact, and Cochran-Armitage Trend tests. Spearman test was used to assess correlation at between the MAX-PC and EPIC at baseline and one-year. Results Baseline overall MAX-PC measures were correlated with measures at one-year (r = 0.5479, p < 0.001). Those reporting high anxiety at one-year were more likely to have Gleason score > 6 (p = 0.004), T-Stage ≥ 2C disease (p = 0.004), and a postoperative prostate-specific antigen (PSA) > 0.1 (p = 0.002); however, this did not apply to all anxious patients. Baseline EPIC sexual function scores were predictive of follow-up EPIC sexual function scores as well (r = 0.5790, p < 0.001). Depression was noted as a problem in 16% of patients at follow-up. Conclusions Our data suggests that the MAX-PC could be used at baseline as a tool to determine who may benefit from psychological intervention pre-PCa and post-PCa treatment. In terms of individualized medicine, behavioral therapy may be the most beneficial in improving HRQOL for younger patients, those with advanced stage disease, and more specifically those whose anxiety outweighs their actual prognosis.

AB - Objective The objective of this paper is to conduct a prospective, longitudinal study employing the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) to examine the baseline and follow-up association of prostate cancer (PCa)-specific anxiety, health-related quality of life (HRQOL), and PCa aggressiveness in men with newly-diagnosed PCa undergoing prostatectomy at our institution. Methods From our prospective PCa registry, we identified a total of 350 men with newly-diagnosed PCa who completed the MAX-PC and the Expanded Prostate Cancer Index Composite (EPIC) at baseline and one-year following surgery. Scores on both measures were compared with clinical measure and demographics using the Wilcoxon Rank Sum, Fisher's exact, and Cochran-Armitage Trend tests. Spearman test was used to assess correlation at between the MAX-PC and EPIC at baseline and one-year. Results Baseline overall MAX-PC measures were correlated with measures at one-year (r = 0.5479, p < 0.001). Those reporting high anxiety at one-year were more likely to have Gleason score > 6 (p = 0.004), T-Stage ≥ 2C disease (p = 0.004), and a postoperative prostate-specific antigen (PSA) > 0.1 (p = 0.002); however, this did not apply to all anxious patients. Baseline EPIC sexual function scores were predictive of follow-up EPIC sexual function scores as well (r = 0.5790, p < 0.001). Depression was noted as a problem in 16% of patients at follow-up. Conclusions Our data suggests that the MAX-PC could be used at baseline as a tool to determine who may benefit from psychological intervention pre-PCa and post-PCa treatment. In terms of individualized medicine, behavioral therapy may be the most beneficial in improving HRQOL for younger patients, those with advanced stage disease, and more specifically those whose anxiety outweighs their actual prognosis.

KW - anxiety

KW - cancer

KW - oncology

KW - prostate cancer

KW - quality of life

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=84926630296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926630296&partnerID=8YFLogxK

U2 - 10.1002/pon.3605

DO - 10.1002/pon.3605

M3 - Article

C2 - 24953309

AN - SCOPUS:84926630296

VL - 24

SP - 451

EP - 457

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 4

ER -